Tocilizumab-aazg for Hemorrhage: Reduction of Ischemic Vascular Events

Part of paid clinical trials in Gainesville, Florida.

Sponsor
University of Florida
Study ID
NCT06863480
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Aneurysmal Subarachnoid Hemorrhage
  • Delayed Cerebral Ischemia

Eligibility Criteria

Sex
ALL
Age
18 Years - 89 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

In this study, tocilizumab-aazg (TYENNE) will be administered to see whether tocilizumab-aazg is safe in patients with a burst brain aneurysm and if it may prevent strokes in patients with a burst brain aneurysm.

Key Dates

Start date
Mar 2, 2026
Status verified
Jan 2026
Primary completion
Jul 30, 2028
Completion
Oct 30, 2028

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: tocilizumab-aazg (TYENNE)
    Participants will receive tocilizumab-aazg 6mg/kg IV infusion drip on Day 0 following subarachnoid hemorrhage and enrollment in the trial.

Primary Outcome Measure

Number of participants with elevation of liver transaminases [ Time Frame: up to 21 days ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Florida Health (UF Health)GainesvilleFlorida32608
Shawna Amini, MPH
[email protected]
352-273-9000
Brian Hoh, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Gainesville, FL

By research site
University of Florida Health (UF Health)· Gainesville, FL

Related Studies